SAN DIEGO, CA / ACCESSWIRE / June 28, 2023 / The Oligonucleotide Therapeutics Society (OTS) is excited to bring together those in the field of oligonucleotide therapeutics for its 19th Annual Oligo Meeting. Anyone interested in oligonucleotide therapeutics is welcome to join the event, which will be held virtually and in person on Oct. 22-25, 2023, in Barcelona, Spain.
OTS is an open, nonprofit forum that fosters academic and industry-based research and the development of oligonucleotide therapeutics. At this year’s meeting, leaders from across the globe will present alongside students, covering topics ranging from antisense, siRNA, immunostimulatory and aptamer applications, RNA/DNA editing, mRNA therapeutics, and basic RNA research.
This year’s keynote speaker will be David Liu, PhD, from the Broad Institute of Harvard and MIT. Liu is known for inventing base editing, a tool for precisely modifying DNA, as well as prime editing, PACE and DNA-templated synthesis – technologies used by thousands of labs worldwide. His many achievements include being elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. Liu has published over 225 papers and is the inventor of over 90 issued U.S. patents.
OTS has the privilege of presenting its Lifetime Achievement Awards, with the 2022 Award going to Sudhir Agrawal, D. Phil, a key player in the discovery and development of RNA therapeutics and the co-inventor of over 400 patents worldwide. As president and founder of ARNAY Sciences LLC, his company’s pioneering publications helped establish antisense as a new drug discovery platform and have contributed to critical discoveries in gapmer antisense and exon skipping.
The 2023 Lifetime Achievement Award will be presented to Cy Stein, MD, PhD, who has over three decades of experience treating prostate and genitourinary cancer patients. Throughout his career, Stein has mixed his love for science with his passion for caring for patients and hopes to continue doing so for many years to come. His four decades of scientific research have primarily been dedicated to developing novel anti-cancer drugs.
As the area of oligonucleotide therapeutics continues to thrive and evolve, OTS will continue to support this vital work, with its annual meeting serving as a dialogue and discussion among industry, academia, and health authorities to educate and share their progress. Currently, over 100 oligonucleotide treatments are in development for common and rare conditions, including cancer and Alzheimer’s disease, and several have received regulatory approval.
OTS looks forward to seeing attendees either in person or online. In-person registration will be closed at 750 delegates, so early registration is recommended for those wishing to attend in person.